HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Canada clarifies labeling regs

This article was originally published in The Rose Sheet

Executive Summary

Cosmetic products with "small, ornamental, non-existent or odd packaging" are addressed in agency's 1clarification of labeling requirements under Canada's Food and Drugs Act. Health department says firms marketing products housed in containers or outside packages so small that they cannot comply with regulations - such as eyeliner pencils, lipsticks or nail enamel - can affix a list of ingredients on a tag, tape or card. It notes that "ingredient list tear-away pads at point of sale, such as those used in the United States for these types of cosmetics," are not accepted for such items under Canadian law. An ingredient list similarly may be affixed to a product container bearing no promotional or advertising material other than a trade-name that "is sold as a decorative ornament in addition to being sold as the container of a cosmetic." A perfume bottle or key chain bauble that contains a lip balm might qualify as such, according to April document. In the case that a container's odd size, shape or texture makes it impractical to attach a tag, tape or card, an ingredient tear-away pad, leaflet or sign can be used "at the point where exposed for sale.

You may also be interested in...



Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel